Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All tixagevimab/cilgavimab..
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchTixagevimab/cilgavimabTixagev../c.. (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Death/hospitalization 92% Improvement Relative Risk Case 47% Tixagevimab/c..  Kertes et al.  Prophylaxis Is prophylaxis with tixagevimab/cilgavimab beneficial for COVID-19? Retrospective 5,124 patients in Israel Lower death/hosp. (p=0.013) and fewer cases (p=0.012) c19early.org Kertes et al., Clinical Infectious Dis.., Jul 2022 Favors tixagevimab/ci.. Favors control

Association between AZD7442 (tixagevimab-cilgavimab) administration and SARS-CoV-2 infection, hospitalization and mortality

Kertes et al., Clinical Infectious Diseases, doi:10.1093/cid/ciac625
Jul 2022  
  Post
  Facebook
Share
  Source   PDF   All   Meta
36th treatment shown to reduce risk in May 2022
 
*, now known with p = 0.000013 from 16 studies, recognized in 30 countries. Efficacy is variant dependent.
Lower risk for mortality, hospitalization, and cases.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments. c19early.org
Retrospective 825 immunocompromised individuals treated with tixagevimab-cilgavimab and 4229 untreated in Israel, showing significantly lower infection and hospitalization/death with treatment. Omicron was the dominant variant.
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron BA.2.75.2, BA.4.6, BQ.1.1 Planas, BA.5, BA.2.75, XBB Haars, ХВВ.1.9.1, XBB.1.9.3, XBB.1.5.24, XBB.1.16, XBB.2.9, BQ.1.1.45, CL.1, and CH.1.1 Pochtovyi.
risk of death/hospitalization, 91.9% lower, RR 0.08, p = 0.01, treatment 1 of 825 (0.1%), control 63 of 4,299 (1.5%), NNT 74, adjusted per study, odds ratio converted to relative risk, multivariable.
risk of case, 47.1% lower, RR 0.53, p = 0.01, treatment 29 of 825 (3.5%), control 308 of 4,299 (7.2%), NNT 27, adjusted per study, odds ratio converted to relative risk, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Kertes et al., 29 Jul 2022, retrospective, Israel, peer-reviewed, 10 authors. Contact: dortal_j@mac.org.il, zeny@013.net.
This PaperTixagev../c..All
Association between AZD7442 (tixagevimab-cilgavimab) administration and SARS-CoV-2 infection, hospitalization and mortality
Jennifer Kertes, Shirley Shapiro, Ben David, Noya Engel-Zohar, Keren Rosen, Avner Kantor, Limor Adler, Miri Mizrahi Reuveni, Arnon Shahar
doi:10.1093/cid/ciac625/6651663
by guest on 30 July 2022 Conclusions AZD7442 among ICI may protect against Omicron variant infection and severe disease, and should be considered for pre-exposure prophylactic AZD7442.
Study limitations: One of the major limitations of the present study is the potential for selection bias in the non-AZD7442 comparison group. It is unknown what proportion of this group never opened the SMS/email, what proportion did open the SMS/mail and decided not to receive AZD7442 and what proportion intended to receive AZD7442 but for whatever reasons, did not complete the process. Persons who refuse treatment and/or lack the motivation required to make/attend an appointment for treatment may be different regarding their healthcare practices from those presenting for treatment. While a large number of potential confounding factors were included in the study, data of this type are not available. It is also possible that those patients entering the study population for conditions requiring active treatment (eg. Anti-CD20) may have more regular contact with the healthcare setting and therefore, more opportunities to be offered AZD7442 (beyond the initial invitation to present). Another major study limitation is the assumption made that all those who were positive for Sars-CoV-2 presented to MHS/outsourced services for testing. Given that the majority of those infected with the Omicron variant experienced mild illness and the availability of antigen hometesting kits, it is likely that not all those infected would test in the HMO/IMOH-appointed services, despite MOH directives. This would explain why in the present study, infection rates were lower in lower socioeconomic..
References
Bar-On, Goldberg, Mandel, Protection by a fourth dose of BNT162b2 against Omicron in Israel, N Engl J Med
Benotmane, Velay, Vargas, Pre-exposure prophylaxis with 300 mg Evusheld elicits limited neutralizing activity against Omicron Variant, Kidney Int
Levin, Ustianowski, De Wit, Intramuscular AZD7442 (Ticagevimab-CIlgavimab) for prevention of Covid-19, N Engl J Med
Liu, Iketani, Guo, Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2, Nature
Montgomery, Hobbs, Padilla, Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19
Schubert, Bertoglio, Steinke, Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant, BMC Med
Tackle, ): a phase 3, randomized, double-blind, placebo-controlled trial, Lancet Respir Med
{ 'DOI': '10.1093/cid/ciac625', 'ISSN': ['1058-4838', '1537-6591'], 'URL': 'http://dx.doi.org/10.1093/cid/ciac625', 'abstract': '<jats:title>Abstract</jats:title>\n' ' <jats:sec>\n' ' <jats:title>Background</jats:title>\n' ' <jats:p>Intramuscular AZD7442 (Tixagevimab–Cilgavimab, (Evusheld)) has been ' 'found effective among immunocompromised individuals (ICI) in reducing Sars-Cov-2 infection ' 'and severe disease in ICIs. We evaluated the association between AZD7442 administration and ' 'SARS-CoV-2 infection and severe disease (COVID-19 hospitalization and all-cause mortality) ' 'among selected ICIs, during a fifth Omicron-dominated wave of COVID-19 (Dec 2021-April 2022) ' 'in Israel.</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Methods</jats:title>\n' ' <jats:p>ICIs aged 12 and over identified in the Maccabi HealthCare Services ' 'database were invited by SMS/email to receive AZD7442. Demographic information, ' 'comorbidities, coronavirus vaccination and prior SARS-CoV-2 infection and COVID-19 outcome ' 'data (infection, severe disease), were extracted from the database. Rates of infection and ' 'severe disease were compared between those administered AZD7442 and those who did not respond ' 'to the invitation, over a three-month period.</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Results</jats:title>\n' ' <jats:p>Of all 825 ICIs administered AZD7442, 29 (3.5%) became infected ' 'with SARS-CoV-2 compared to 308 (7.2%) of 4299 ICIs not administered AZD7442 (p\u2009' '&amp;lt;\u20090.001). After adjustment, the AZD7442 group were half as less likely to become ' 'infected with Sars-Cov-2 than the non-administered group (OR: 0.51, 95% CI: 0.30-0.84). One ' 'person in the AZD7442 group (0.1%) was hospitalized for COVID-19 compared to 27 (0.6%) in the ' 'non-administered group (p\u2009=\u20090.07). No mortality was recorded among the AZD7442 ' 'group, compared to 40 deaths (0.9%) in the non-administered group (p\u2009=\u20090.005). ' 'After adjustment, ICIs administered AZD7442 were 92% less likely to be hospitalized/die than ' 'those not administered AZD7442 (OR: 0.08, 95% CI: 0.01-0.54).</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Conclusions</jats:title>\n' ' <jats:p>AZD7442 among ICI may protect against Omicron variant infection and ' 'severe disease, and should be considered for pre-exposure prophylactic AZD7442.</jats:p>\n' ' </jats:sec>', 'author': [ { 'affiliation': [ { 'name': 'Dept Health Evaluation & Research, Maccabi HealthCare Services , ' 'Tel Aviv-Jaffa , Israel'}], 'family': 'Kertes', 'given': 'Jennifer', 'sequence': 'first'}, { 'affiliation': [ { 'name': 'Division of Health, Maccabi HealthCare Services , Tel Aviv-Jaffa ' ', Israel'}, { 'name': 'Tel Aviv University, Sackler Faculty of Medicine, Dept of Family ' 'Medicine , Tel Aviv , Israel'}], 'family': 'David', 'given': 'Shirley Shapiro Ben', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Division of Data & Digital Health, Maccabi HealthCare Services , ' 'Tel Aviv-Jaffa , Israel'}], 'family': 'Engel-Zohar', 'given': 'Noya', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Dept Health Evaluation & Research, Maccabi HealthCare Services , ' 'Tel Aviv-Jaffa , Israel'}, { 'name': 'Tel Aviv University, Sackler Faculty of Medicine, Dept of Family ' 'Medicine , Tel Aviv , Israel'}], 'family': 'Rosen', 'given': 'Keren', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Dept Health Evaluation & Research, Maccabi HealthCare Services , ' 'Tel Aviv-Jaffa , Israel'}], 'family': 'Hemo', 'given': 'Beatriz', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Dept Health Evaluation & Research, Maccabi HealthCare Services , ' 'Tel Aviv-Jaffa , Israel'}], 'family': 'Kantor', 'given': 'Avner', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Dept Health Evaluation & Research, Maccabi HealthCare Services , ' 'Tel Aviv-Jaffa , Israel'}, { 'name': 'Tel Aviv University, Sackler Faculty of Medicine, Dept of Family ' 'Medicine , Tel Aviv , Israel'}], 'family': 'Adler', 'given': 'Limor', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Dept Health Evaluation & Research, Maccabi HealthCare Services , ' 'Tel Aviv-Jaffa , Israel'}], 'family': 'Stein', 'given': 'Naama Shamir', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Division of Health, Maccabi HealthCare Services , Tel Aviv-Jaffa ' ', Israel'}], 'family': 'Reuveni', 'given': 'Miri Mizrahi', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Division of Data and Digital Health, Maccabi HealthCare Services ' ', Tel Aviv-Jaffa , Israel'}], 'family': 'Shahar', 'given': 'Arnon', 'sequence': 'additional'}], 'container-title': 'Clinical Infectious Diseases', 'content-domain': {'crossmark-restriction': False, 'domain': []}, 'created': {'date-parts': [[2022, 7, 29]], 'date-time': '2022-07-29T11:29:56Z', 'timestamp': 1659094196000}, 'deposited': { 'date-parts': [[2022, 7, 29]], 'date-time': '2022-07-29T11:29:56Z', 'timestamp': 1659094196000}, 'indexed': {'date-parts': [[2022, 7, 30]], 'date-time': '2022-07-30T04:29:22Z', 'timestamp': 1659155362504}, 'is-referenced-by-count': 0, 'issued': {'date-parts': [[2022, 7, 29]]}, 'language': 'en', 'license': [ { 'URL': 'https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model', 'content-version': 'am', 'delay-in-days': 0, 'start': { 'date-parts': [[2022, 7, 29]], 'date-time': '2022-07-29T00:00:00Z', 'timestamp': 1659052800000}}], 'link': [ { 'URL': 'https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciac625/45186210/ciac625.pdf', 'content-type': 'application/pdf', 'content-version': 'am', 'intended-application': 'syndication'}, { 'URL': 'https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciac625/45186210/ciac625.pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'member': '286', 'original-title': [], 'prefix': '10.1093', 'published': {'date-parts': [[2022, 7, 29]]}, 'published-online': {'date-parts': [[2022, 7, 29]]}, 'publisher': 'Oxford University Press (OUP)', 'reference-count': 0, 'references-count': 0, 'relation': {}, 'resource': { 'primary': { 'URL': 'https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciac625/6651663'}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subject': ['Infectious Diseases', 'Microbiology (medical)'], 'subtitle': [], 'title': 'Association between AZD7442 (tixagevimab-cilgavimab) administration and SARS-CoV-2 infection, ' 'hospitalization and mortality', 'type': 'journal-article'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit